This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Teva’s patent, disparagement strategies for MS drug attract EU antitrust fine

( October 31, 2024, 11:02 GMT | Official Statement) -- MLex Summary: The European Commission has imposed a sanction of 462.6 million euros on Teva Pharmaceutical for abusing the patent system to protect its blockbuster multiple sclerosis drug Copaxone. It was also sanction for a campaign of denigrating a rival drug towards doctors and healthcare authorities. This is the first time the EU authority has found that these kinds of behavior break antitrust law.The press release is attached. A statement from EU commissioner Margrethe Vestager is also attached. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login